admin

Denison Mines (NYSEAMERICAN:DNN) is a Canadian uranium mining company with an outsized valuation and penny stock status. As such, investors should be careful about investing in DNN stock, as it is likely to be quite volatile. Source: Shutterstock The Toronto-based company has a major prospective uranium mining project in northern Saskatchewan called the Wheeler River
0 Comments
Until recently, Ocugen (NASDAQ:OCGN) stock was trading below $1 a share. This biotech company, which was founded in 2013, did not have much traction with its various drug candidates. Source: Shutterstock But things changed in a big way when Ocugen announced a partnership with Bharat Biotech, which is based in India. The company is the
0 Comments
Check out how to buy a single call option on the TD Ameritrade ThinkorSwim Platform! Increase your knowledge and invest smartly! #thinkorswim #calloption #tradingplatform Posted at: https://tradersfly.com/blog/buying-a-single-call-option-on-the-td-ameritrade-thinkorswim-platform/ ? BECOME A MEMBER NOW https://members.tradersfly.com/ ? GET MY FREEBIES Freebies ? SUBMIT A VOICE QUESTION Question – Hungry for Returns ? START HERE: FOR NEW TRADERS Start
0 Comments
When most people think of an “intervention,” they friends and family gathered to demand a loved one seek treatment for alcohol or drug abuse. The person, overwhelmed by the outpouring of love and concern, hopefully agrees to receive the life-saving treatment. The same principles used to intervene in substance abuse can also be applied to
0 Comments
Take a look at some of the biggest movers in the premarket: AstraZeneca (AZN) – The drugmaker said a U.S. study showed its Covid-19 vaccine had 79% efficacy in preventing symptomatic illness, 100% effectiveness against critical disease and hospitalization, and did not pose a higher risk of blood clots. AstraZeneca shares gained 2.2% in premarket
0 Comments
New Jersey-based Citius Pharmaceuticals (NASDAQ:CTXR) could simply be pigeonholed as a medical product company. But that’s an oversimplification. Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. Source: Iryna Imago / Shutterstock.com Citius describes itself as a “late-stage specialty pharmaceutical company” that develops and commercializes “critical care products, with a particular
0 Comments
If you don’t mind adding an element of mystery to your portfolio, consider Pershing Square Tontine Holdings (NYSE:PSTH). Just be advised that, by acquiring PSTH stock, you’ll own a stake in a special purpose acquisition company (SPAC) with a yet unspecified merger target. Source: Dmitry Demidovich/ShutterStock.com Back in January of this year, I cautioned prospective investors
0 Comments
A Starlink user terminal being set up. SpaceX Elon Musk’s SpaceX is in talks with the United Kingdom for the company’s Starlink satellite unit to potentially to earn funding as a part of the government’s new $6.9 billion internet infrastructure program, CNBC confirmed. U.K. Minister for Digital Infrastructure Matt Warman recently met with Starlink leadership,
0 Comments
One of the latest meme stocks to capture investor imagination was Roblox (NYSE:RBLX). The company went public via a direct listing on March 10 and shares quickly advanced far beyond the $45 initial price. Not only have the gains held, but RBLX is now up to over $70 per share. And with $1,400 stimulus checks
0 Comments
Access free tools and notes to these lessons at: http://www.BuffettsBooks.com Preston Pysh is the #1 selling Amazon author of two books on Warren Buffett. The books can be found at the following location: In this lesson, we learned the importance of always understanding the consequences of our actions. Buying and selling stock can have an
0 Comments
It’s coming any minute now. You’re refreshing the investor relations page constantly, cursing your unbelievably slow WiFi, twitching in anticipation of the latest earnings report. The stock has been slipping for weeks, and the TV pundits are saying the company’s peaked — time to cash out and move on. You know they’re wrong — the analysts, the short-sellers. They’re
0 Comments